Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lauren Breshears

Nurse Practitioner, Primary Care Columbia, MO Nurse Practitioner

NPI 1861887689 CMS profile 10713596

900 W Nifong Blvd Ste 101, Columbia, MO 65203

Open in the dashboard

General payments

$1,178

15 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lauren Breshears of Columbia, MO is reported in the CMS Open Payments database as having received $1,178 across 15 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $316 3
2024 General $483 5
2023 General $242 4
2022 General $16 1
2021 General $120 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lauren Breshears
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Lauren Breshears were reported at $316. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Lauren Breshears Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $120 $137 $39–$445 $132
2022 $16 $139 $44–$421 $149
2023 $242 $163 $53–$481 $160
2024 $483 $176 $54–$511 $164
2025 $316 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $548 5 payments
  2. Novo Nordisk Inc $277 3 payments
  3. Phathom Pharmaceuticals, Inc. $127 1 payment
  4. Amgen Inc. $126 1 payment
  5. Dexcom, Inc. $26 1 payment
  6. Merck Sharp & Dohme Corporation $21 1 payment
  7. Ethicon US, LLC $20 1 payment
  8. Sanofi Pasteur Inc. $16 1 payment
  9. Lilly USA, LLC $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,178 15 payments
Products named General payments · program years 2021–2025
  1. AIRSUPRA $230 2 payments
  2. BREZTRI $217 2 payments
  3. VOQUEZNA $127 1 payment
  4. Repatha $126 1 payment
  5. RYBELSUS $105 1 payment
  6. FARXIGA $100 1 payment
  7. Wegovy $70 1 payment
  8. Dexcom G6 Transmitter $26 1 payment
  9. GARDASIL 9 $21 1 payment
  10. CAPVAXIVE $21 1 payment
  11. Other $88 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 132 drugs

Part D claims

9,618

Median for Nurse Practitioner: 389

Drug cost

$628,478

Median for Nurse Practitioner: $21,885

Branded share of claims

17.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 92 $119,793
Eliquis Apixaban Brand 111 $99,448
Mounjaro Tirzepatide Brand 63 $74,845
Myrbetriq Mirabegron Brand 63 $40,956
Jardiance Empagliflozin Brand 33 $24,776
Januvia Sitagliptin Phosphate Brand 37 $24,569
Farxiga Dapagliflozin Propanediol Brand 24 $20,565
Trulicity Dulaglutide Brand 15 $20,247
Xarelto Rivaroxaban Brand 14 $17,236
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 26 $12,361

The 10 drugs with the highest cost, of 132 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$103,833

Of which drugs: $15,826

Medicare patients

482

Average age 75

Services billed

1,287

299 women, 183 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 51%
Diabetes 23%
Depression 23%
Ischemic heart disease 21%
Osteoporosis 17%
Atrial fibrillation 16%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 20 20 $5,759
Pneumococcal conjugate vaccine, 15 valent (pcv15), for intramuscular use 90671 Office 12 12 $2,982
Sarscv2 vac 30mcg trs-suc im 91320 Office 17 18 $2,531
Vaccine for influenza for injection into muscle 90662 Office 23 23 $1,882

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $127
$127 — —
Repatha
  • Amgen Inc. $126
$126 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $107
$107 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $100
$100 24 —
GARDASIL 9
  • Merck Sharp & Dohme Corporation $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

15 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record